Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

NCT02900651 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
139
Enrollment
INDUSTRY
Sponsor class

Stopped The decision of early termination was made due to business reasons, and was not based on any safety or tolerability concerns for MAK683

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals